Literature DB >> 40693

Characterization of an established cell line from human renal carcinoma.

M Matsuda, M Osafune, E Nakano, T Kotake, T Sonoda, S Watanabe, T Hada, T Okochi, K Higashino, Y Yamamura, T Abe.   

Abstract

A cell line, designated as OUR-10, has been established from a renal carcinoma in a Japanese woman. This cell line forms monolayers of polygonal epithelial cells with scattered round or dendritic cells and exhibits multilayering. With electron microscopy, differentiated surface structures that resemble the microvilli characteristic of renal carcinomas can be seen even at the 60th transfer. The cells have a hypodiploid karyotype with modal numbers of 39 and 40. No marker chromosomes were seen, but definite nonrandom loss of three chromosomes in Group D and one in Group E were recognized. The doubling time was estimated as approximately 32 hr in exponentially growing cultures, and the cells formed colonies in soft agar with an average efficiency of 25%. Heterotransplantation into the cheek pouch of immunosuppressed hamsters produced tumors that were histologically similar to the original cancerous tissue. The electrophoretic mobility of gamma-glutamyl transpeptidase extracted from the cells coincided with that of a novel isozyme found in human renal carcinoma tissue, and the genetic phenotype of the glucose-6-phosphate dehydrogenase was proved to be the B phenotype. The antigenic structure of HLA was determined as HLA-A2, 11; B5, 40, which was the same as that of peripheral blood lymphocytes of the woman with renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 40693

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters.

Authors:  N Miyao; T Tsukamoto; Y Kumamoto
Journal:  Urol Res       Date:  1989

2.  Establishment and characterization of a new human renal cell carcinoma cell line (KRC/Y).

Authors:  H Yano; M Maruiwa; S Sugihara; M Kojiro; S Noda; K Eto
Journal:  In Vitro Cell Dev Biol       Date:  1988-01

3.  Evidence for proximal tubular cell origin of a sarcomatoid variant of human renal cell carcinoma.

Authors:  D A Terreros; A Behbehani; F E Cuppage
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma.

Authors:  C D Gerharz; R Moll; S Störkel; U Ramp; B Hildebrandt; G Molsberger; P Koldovsky; H E Gabbert
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

5.  Human renal cell carcinoma: establishment and characterization of a new cell line (OS-RC-2).

Authors:  T Kinouchi; T Kotake; Y Mori; T Abe
Journal:  In Vitro Cell Dev Biol       Date:  1985-04

6.  Human renal clear cell carcinoma: establishment and characterization of a new cell line (G-2101).

Authors:  P H Gumerlock; B F Edwards; A D Deitch; F J Meyers
Journal:  In Vitro Cell Dev Biol       Date:  1988-05

7.  Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type.

Authors:  C D Gerharz; U Ramp; J Olert; R Moll; S Störkel; N Marx; H E Gabbert
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines.

Authors:  C D Gerharz; B Hildebrandt; R Moll; U Ramp; M Sarbia; S Störkel; P Koldovsky; H E Gabbert
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

9.  EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.

Authors:  Mototaka Sato; Yasutomo Nakai; Wataru Nakata; Takahiro Yoshida; Koji Hatano; Atsunari Kawashima; Kazutoshi Fujita; Motohide Uemura; Hitoshi Takayama; Norio Nonomura
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.